Quick Answer
Arbutus Biopharma Corp reported Cash and Equivalents of $18.01 million for fiscal year 2025.
Arbutus Biopharma Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.01M | -50.4% |
| 2024 | $36.33M | +38.2% |
| 2023 | $26.29M | -14.6% |
| 2022 | $30.78M | -71.8% |
| 2021 | $109.28M | +109.1% |
| 2020 | $52.25M | +64.3% |
| 2019 | $31.80M | -13.9% |
| 2018 | $36.94M | -32.0% |
| 2017 | $54.29M | +131.9% |
| 2016 | $23.41M | -86.0% |
| 2015 | $166.78M | +131.0% |
| 2014 | $72.19M | +5.0% |
| 2013 | $68.72M | +46.1% |
| 2012 | $47.02M | +420.7% |
| 2011 | $9.03M | -27.2% |
| 2010 | $12.41M | -49.1% |
| 2009 | $24.40M | -6.9% |
| 2008 | $26.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.41M | -29.6% | -40.1% |
| June 30, 2025 | $37.41M | -40.4% | +0.9% |
| March 31, 2025 | $37.08M | -14.0% | +2.1% |
| December 31, 2024 | $36.33M | +38.2% | +14.1% |
| September 30, 2024 | $31.85M | +81.7% | -49.3% |
| June 30, 2024 | $62.79M | +130.9% | +45.7% |
| March 31, 2024 | $43.10M | +6.2% | +64.0% |
| December 31, 2023 | $26.29M | -14.6% | +49.9% |
- Arbutus Biopharma Corp showed a decrease of -50.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Arbutus Biopharma Corp’s cash and equivalents has declined by 31.3% (from $26.22 million to $18.01 million).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: